Ana Fernandez-Cruz
Overview
Explore the profile of Ana Fernandez-Cruz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
68
Citations
1159
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lopez-Medrano F, Carver P, Rutjanawech S, Aranha-Camargo L, Fernandes R, Belga S, et al.
Transplantation
. 2024 Jul;
109(2):e134-e141.
PMID: 39049076
Background: The management and outcomes of nontuberculous mycobacterial (NTM) infections in solid organ transplant (SOT) recipients are poorly characterized. We aimed to describe the management and 1-y mortality of these...
2.
Gutierrez-Villanueva A, Quintana-Reyes C, Martinez de Antonio E, Rodriguez-Alfonso B, Velasquez K, de la Iglesia A, et al.
Microorganisms
. 2024 Feb;
12(2).
PMID: 38399711
Febrile neutropenia (FN) is a complication of hematologic malignancy therapy. An early diagnosis would allow optimization of antimicrobials. The F-FDG-PET-CT may be useful; however, its role is not well established....
3.
Calderon-Parra J, Gutierrez-Villanueva A, Ronda-Roca G, Jimenez M, de la Torre H, Rodenas-Baquero M, et al.
Int J Antimicrob Agents
. 2024 Jan;
63(3):107095.
PMID: 38244814
Introduction: Antivirals and monoclonal antibodies lower the risk of progression in immunocompromised patients. However, combination therapy with both types of agents has not been studied. Patients And Methods: This was...
4.
Ramos-Martinez A, Gonzalez-Merino P, Suanzes-Martin E, la Fuente M, Escudero-Lopez G, Andres-Eisenhofer A, et al.
Sci Rep
. 2023 Sep;
13(1):15613.
PMID: 37730691
Coagulase-negative staphylococci (CoNS) are currently considered typical microorganisms causing infective endocarditis (IE) in patients with prosthetic valves. The objective was to determine variables associated with IE in patients with CoNS...
5.
Lamoth F, Nucci M, Fernandez-Cruz A, Azoulay E, Lanternier F, Bremerich J, et al.
Med Mycol
. 2023 Jun;
61(7).
PMID: 37381179
The (1→3)-β-D-glucan (BDG) is a component of the fungal cell wall that can be detected in serum and used as an adjunctive tool for the diagnosis of invasive mold infections...
6.
Gutierrez A, Rodriguez B, Velasquez K, Gutierrez I, Garcia S, Munez E, et al.
BMJ Open
. 2023 Jun;
13(6):e074240.
PMID: 37355275
Introduction: The evaluation of staging and activity of invasive fungal infection (IFI) is used to adjust the type and duration of antifungal therapy (AT). Typically anatomy-based imaging is used. Positron...
7.
Moreno-Torres V, Martinez-Urbistondo M, Calderon-Parra J, Mills P, Munoz-Serrano A, Arias-Milla A, et al.
Int J Infect Dis
. 2023 Jun;
134:154-159.
PMID: 37321473
Objectives: Underlying immunodeficiency has been associated with worse clinical presentation and increased mortality in patients with COVID-19. We evaluated the mortality of solid organ transplant (SOT) recipients (SOTR) hospitalized in...
8.
Puerta-Alcalde P, Monzo-Gallo P, Aguilar-Guisado M, Ramos J, Laporte-Amargos J, Machado M, et al.
J Infect
. 2023 May;
87(1):46-53.
PMID: 37201859
Objectives: We describe the current epidemiology, causes, and outcomes of breakthrough invasive fungal infections (BtIFI) in patients with haematologic malignancies. Methods: BtIFI in patients with ≥ 7 days of prior...
9.
Diego-Yague I, Mora-Vargas A, Vazquez-Comendador J, Santamarina-Alcantud B, Fernandez-Cruz A, Munez-Rubio E, et al.
Clin Microbiol Infect
. 2023 Feb;
29(6):744-750.
PMID: 36773773
Objectives: We aimed to analyse the efficacy and safety of oral sequential therapy (OST) in uncomplicated Staphylococcus aureus bacteraemia (SAB). Methods: Single-centre observational cohort at a tertiary hospital in Spain,...
10.
Calderon-Parra J, Guisado-Vasco P, Montejano-Sanchez R, Estrada V, Cuevas-Tascon G, Aguareles J, et al.
J Clin Med
. 2023 Feb;
12(3).
PMID: 36769511
Objective: We aim to describe the safety and efficacy of sotrovimab in severe cases of COVID-19 in immunocompromised hosts. Methods: We used a retrospective multicenter cohort including immunocompromised hospitalized patients...